Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Next Vial vs WeightCare

By GLP-1 ScorecardUpdated

Next VialFactor scores not reassessed.
Site position #377

Higher score

WeightCareFactor scores not reassessed.
Site position #498

Lower score

Score comparison

Next Vial has the higher recorded score — 59.3/100 to 52.2/100.

Next Vial grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options.

Before you choose

Before comparing the headline prices, the Next Vial review and the WeightCare review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Next Vial vs WeightRx and Peak Wellness vs WeightCare compare each of them with another graded program, and the list of alternatives to Next Vial ranks the programs closest to Next Vial on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the HumeCare+ review covers one graded close to these two, at 58.6/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNext Vial +5
40
35
Dose & formulationWeightCare +10
52
62
Clinical oversightNext Vial +27
82
55
Labs & monitoringWeightCare +2
52
54
FulfillmentNext Vial +14
86
72
Contract termsNext Vial +14
55
41
Next Vial · top barWeightCare · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNext VialWeightCare
WeighScore59.3/10052.2/100
GradeCC
Site position#377#498
Semaglutide$250/mo (compounded)$249/mo on a 3-month plan ($139/mo on a 12-month plan)
TirzepatideNot disclosed$299/mo on a 3-month starter plan ($216/mo on a 12-month plan, any dose)
Coverage49 statesCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Next Vial

Site position #377 · C

Factor scores not reassessed.

Strengths

  • LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
  • No membership fees — one all-in price covering consultation, medication, and shipping
  • Compounded semaglutide, tirzepatide, and microdose options available
  • Free rushed shipping; serves 49 states nationwide
  • Board-certified physician oversight with ongoing provider support

What to consider

  • Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
  • Compounded medications are not FDA-approved
  • Labs and nutritional coaching not disclosed
  • Microdose pricing not published on product page
  • Alaska not listed among served states
WeightCare

Site position #498 · C

Factor scores not reassessed.

FDAWarning letter issued to Weightless Medical LLC dba WeightCare in February 2026. See the FDA warning-letter database.

Strengths

  • PCAB-accredited pharmacy partners — strongest pharmacy quality signal
  • Quality testing: potency and sterility per USP 797 standards
  • 85,000+ members since 2022 — established patient base
  • Multiple program tiers for semaglutide
  • Health coaching, dietitians, fitness trainers included

What to consider

  • No LegitScript certification on the site itself
  • State availability not explicitly listed
  • Compounded only — no brand-name options
  • The lowest rates ($139 semaglutide, $216 tirzepatide) require a 12-month plan; 3-month plans are $249 and $299
  • FDA issued Weightless Medical LLC dba WeightCare a warning letter in February 2026; the letter is public in FDA's warning-letter database

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard